Review article · 2026 · Open access

Drug Repurposing in Pre‐Eclampsia: Maternal Pharmacokinetic and Pharmacodynamic Considerations for Clinical Trial Design

Cassius M. Phogole, Engi Abd Elhady Algharably, Eric H. Decloedt, Catherine Anne Cluver, Veshni Pillay-Fuentes Lorente

Clinical Pharmacology & Therapeutics · Published 13 November 2026 · DOI 10.1002/cpt.70568

Open PDFView at the publisherCite this paper

In brief

“Drug Repurposing in Pre‐Eclampsia: Maternal Pharmacokinetic and Pharmacodynamic Considerations for Clinical Trial Design” is a 2026 review article by Cassius M. Phogole and 4 co-authors, published in Clinical Pharmacology & Therapeutics. OpenAlex counts 0 citations as of 18 November 2026. It is open access under a CC BY-NC licence: the full text is free to read at Clinical Pharmacology & Therapeutics.

Citations
0
References
25
Authors
5

Abstract

Pre-eclampsia is a hypertensive disorder of pregnancy affecting 3-8% of pregnancies worldwide, with no disease-modifying therapy currently available. Drug repurposing offers a promising strategy, yet no candidate has been validated to date. Pregnancy-associated physiological changes alter drug pharmacokinetics (PK), and pre-eclampsia itself may further modify drug disposition, complicating dose selection and contributing to inconclusive clinical trial outcomes. A structured literature search identified six prospective or randomized controlled trials of repurposed drugs for established pre-eclampsia: esomeprazole, omeprazole, sulfasalazine, pravastatin, recombinant antithrombin, and metformin. All drugs were well tolerated, with metformin the one to show promising clinical benefit by prolonging gestation; the remaining five drugs yielded inconclusive or null efficacy outcomes. Critically, PK sampling was conducted in only three trials, and none systematically characterized exposure-response relationships using key pre-eclampsia biomarkers, including soluble fms-like tyrosine kinase-1, soluble endoglin, and placental growth factor. Further common methodological limitations included small sample sizes (12-120 participants), heterogeneous gestational age eligibility criteria, and dosing regimens extrapolated from non-pregnant populations without pregnancy-specific optimization. These shortcomings likely contributed to the translational gap between promising preclinical findings and positive clinical trial outcomes. Model-informed drug development (MIDD) approaches, including physiologically based pharmacokinetic (PBPK) and population pharmacokinetic (popPK) modeling, optimal sampling strategies, and simulation-based dose selection, offer a framework to improve pre-eclampsia trial design. Future studies should integrate these approaches with biomarker-guided exposure-response analyses and prediction of fetal exposure throughout pregnancy to enhance therapeutic development, optimize maternal-fetal safety, and accelerate the identification of effective disease-modifying therapies for pre-eclampsia.

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Phogole, C. M., Algharably, E. A. E., Decloedt, E. H., Cluver, C. A., & Lorente, V. P.-F. (2026). Drug Repurposing in Pre‐Eclampsia: Maternal Pharmacokinetic and Pharmacodynamic Considerations for Clinical Trial Design. Clinical Pharmacology & Therapeutics. https://doi.org/10.1002/cpt.70568

MLA 9

Phogole, Cassius M., et al. “Drug Repurposing in Pre‐Eclampsia: Maternal Pharmacokinetic and Pharmacodynamic Considerations for Clinical Trial Design.” Clinical Pharmacology & Therapeutics, 2026. https://doi.org/10.1002/cpt.70568.

Chicago

Phogole, Cassius M., Engi Abd Elhady Algharably, Eric H. Decloedt, Catherine Anne Cluver, and Veshni Pillay-Fuentes Lorente. 2026. “Drug Repurposing in Pre‐Eclampsia: Maternal Pharmacokinetic and Pharmacodynamic Considerations for Clinical Trial Design.” Clinical Pharmacology & Therapeutics. https://doi.org/10.1002/cpt.70568.

Harvard

Phogole, C. M. et al. (2026) ‘Drug Repurposing in Pre‐Eclampsia: Maternal Pharmacokinetic and Pharmacodynamic Considerations for Clinical Trial Design’, Clinical Pharmacology & Therapeutics. doi:10.1002/cpt.70568.

IEEE

C. M. Phogole, E. A. E. Algharably, E. H. Decloedt, C. A. Cluver, and V. P.-F. Lorente, “Drug Repurposing in Pre‐Eclampsia: Maternal Pharmacokinetic and Pharmacodynamic Considerations for Clinical Trial Design,” Clinical Pharmacology & Therapeutics, 2026, doi: 10.1002/cpt.70568.

BibTeX

@article{phogole2026drug,
  title     = {{Drug Repurposing in Pre‐Eclampsia: Maternal Pharmacokinetic and Pharmacodynamic Considerations for Clinical Trial Design}},
  author    = {Phogole, Cassius M. and Algharably, Engi Abd Elhady and Decloedt, Eric H. and Cluver, Catherine Anne and Lorente, Veshni Pillay-Fuentes},
  journal   = {Clinical Pharmacology \& Therapeutics},
  year      = {2026},
  doi       = {10.1002/cpt.70568},
  url       = {https://doi.org/10.1002/cpt.70568}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Topic and keywords

Health Sciences › Medicine › Obstetrics and Gynecology › Pregnancy and preeclampsia studies

  • preeclampsia
  • drug repurposing
  • pharmacodynamics
  • clinical trial design
  • metformin
  • esomeprazole
  • omeprazole
  • sulfasalazine

Work with this paper

Most-cited papers in Medicine

All highly cited Medicine papers

Questions about this paper

How do I cite this paper in APA style?

Phogole, C. M., Algharably, E. A. E., Decloedt, E. H., Cluver, C. A., & Lorente, V. P.-F. (2026). Drug Repurposing in Pre‐Eclampsia: Maternal Pharmacokinetic and Pharmacodynamic Considerations for Clinical Trial Design. Clinical Pharmacology & Therapeutics. https://doi.org/10.1002/cpt.70568

How many times has this paper been cited?

0 times, according to OpenAlex on 18 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

Yes. It is open access at Clinical Pharmacology & Therapeutics: sign in and open the PDF from this page.

Who wrote this paper?

Cassius M. Phogole, Engi Abd Elhady Algharably, Eric H. Decloedt, Catherine Anne Cluver, Veshni Pillay-Fuentes Lorente.

What is the DOI of this paper?

10.1002/cpt.70568, permanently at https://doi.org/10.1002/cpt.70568. Sign in and open it from this page.

Bibliographic data from OpenAlex (CC0), last checked 18 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.